Accelerated approvals: Early-phase success or premature authorization?
- PMID: 39393358
- DOI: 10.1016/j.ccell.2024.09.005
Accelerated approvals: Early-phase success or premature authorization?
Abstract
We compare the clinical trial success rates of products receiving US Food and Drug Administration (FDA) accelerated approval (AA) to those approved without using this pathway. Our findings raise important questions about how the AA pathway can best optimize early access to therapeutics that are ultimately proven safe and effective.
Copyright © 2024 Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of interests G.C.A. is past chair of the FDA’s Peripheral and Central Nervous System Advisory Committee and a co-founding principal and equity holder in Stage Analytics. These arrangements have been reviewed and approved by Johns Hopkins University in accordance with its conflict-of-interest policies.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical